Curi Bio
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2015
- Type
- Corporation Seattle business license
- Employees
- 58
- Registered name
- Nanosurface Biomedical Inc Seattle business license
- Stage
- Startup
- Founders
- Elliot Fisher
Seattle Biotech Startup Curi Bio Raises $10M Led by DreamCIS to Advance 3D Tissue Drug Discovery Platforms
Seattle biotech startup Curi Bio raised $10 million in Series B funding led by DreamCIS to expand its R&D platform using 3D tissue models for drug discovery. The company serves major pharmaceutical firms and aims to develop new platforms for various muscle and metabolic diseases.
Curi Bio raises $10M to advance iPSC-based 3D tissue drug-discovery platforms including Mantarray
Seattle-based Curi Bio raised $10 million in Series A financing to advance its human iPSC-based drug discovery platforms, including 3D engineered tissue products like Mantarray and Cytostretcher. The company provides customized assay and screening services for cardiac, musculoskeletal and neuromuscular models and has prior funding including $6M this spring and over $6M in NIH grants.
Startup Haven launches Startup Haven Ventures, adds Westerdal, Yu and Mbemba; PSL promotes three; Adam Selipsky named AWS CEO
Startup Haven, founded by Bob Crimmins, launched Startup Haven Ventures and expanded its team to include Jay Westerdal, Arry Yu and Claudius Mbemba; the fund targets pre-seed, capital-efficient companies with a Pacific Northwest focus and made its first investment in Verdi. Seattle’s Pioneer Square Labs promoted Palvi Mehta, David Zager and Ben Gilbert; separately, Tableau CEO Adam Selipsky will become AWS CEO, replacing Andy Jassy.
Curi Bio raises $6M Series A led by Dynamk Capital to advance human stem cell drug-discovery platforms
Seattle stem-cell startup Curi Bio raised $6 million in a Series A led by Dynamk Capital to advance its human stem cell platforms for drug discovery, bringing total funding to $16.8 million.
